Company intelligence / Profile preview

Exosla Therapeutics

Essen, North Rhine-Westphalia, Germany

Ownership: Private
Development stage: Other

Overview

Exosla Therapeutics is currently in the pre-clinical stage. The company's research, building on foundational work at the University of Duisburg-Essen, has demonstrated that extracellular vesicles (EVs) derived from immortalized monoclonal mesenchymal stem cell (MSC) lines can protect against neonatal hypoxic-ischemic brain injury in animal models and provide neuroprotective effects in neuroinflammatory contexts.

Therapeutic areas: OphthalmologyCardiovascularImmunologyNeurology
Modalities: Exosome-based therapyBiologic
Industry: Biotech

Partnerships

University of Duisburg-Essen

Beyond the preview

Go deeper on Exosla Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exosla Therapeutics.

Explore the full profile